|[April 14, 2014]
Research and Markets: Global Cariprazine Use for Schizophrenia - Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/5z4vzf/cariprazine)
has announced the addition of the "Cariprazine
(Schizophrenia) - Forecast and Market Analysis to 2022" report
to their offering.
Cariprazine is a D3-preferring D3/D2 receptor partial agonist under
development for the treatment of schizophrenia, bipolar mania, and major
depressive disorder by Hungary-based Gedeon Richter and Forest. While
maintainig highest affinity for D3 receptors, cariprazine also has low
potency at 5-HT2C, H1, and adrenergic receptor sites.
Overview of Schizophrenia, including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview
on the competitive landscape.
Detailed information on Cariprazine including product description,
safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Cariprazine for the top seven countries from 2012
Sales information covered for the US, France, Germany, Italy, Spain,
the UK and Japan
Key Topics Covered:
Tables & Figures
Opportunity and Unmet Need
For more information visit http://www.researchandmarkets.com/research/5z4vzf/cariprazine
[ Back To TMCnet.com's Homepage ]